Premium
Tretinoin: A review of preclinical toxicological studies
Author(s) -
Cohen Marvin
Publication year - 1993
Publication title -
drug development research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.582
H-Index - 60
eISSN - 1098-2299
pISSN - 0272-4391
DOI - 10.1002/ddr.430300407
Subject(s) - tretinoin , toxicity , acute promyelocytic leukemia , retinoic acid , pharmacology , medicine , sister chromatid exchange , alkaline phosphatase , ames test , carcinogen , chemistry , biology , biochemistry , in vitro , enzyme , genetics , salmonella , bacteria , gene
Tretinoin (all‐trans‐retinoic acid) has shown efficacy in the treatment of acute promyelocytic leukemia. The preclinical toxicological profile of tretinoin was similar to that of other retinoids. The compound had a relatively low acute toxicity; repeated doses resulted in a substantial increase in toxicity that was a function of dose and duration of exposure. Bone fractures, elevated alkaline phosphatase, and testicular degeneration were produced by repeated doses of tretinoin. Teratogenicity was demonstrated in several species. Tretinoin was inactive in the Ames test but appeared to induce sister‐chromatid exchanges in human diploid fibroblasts. Insufficient data are available to evaluate the carcinogenic potential of tretinoin. © 1993 wiley‐Liss, Inc.